|

Triapine Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since June 2026

Also known as: 3-AP, 3-Apct, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, OCX-0191, OCX-191 +2 more

Pipeline

Phase 1: 2

Top Sponsors

  • Northwestern University1
  • National Cancer Institute (NCI)1

Indications

  • Recurrent Glioblastoma, IDH-Wildtype2
  • Cancer2
  • Recurrent WHO Grade 2 Glioma1
  • Recurrent Astrocytoma, IDH-Mutant, Grade 31
  • Recurrent Astrocytoma, IDH-Mutant1

Duarte, California1 trial

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

City of Hope Comprehensive Cancer Center

Phase 1

Chicago, Illinois1 trial

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Northwestern University

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.